MODULE 2 7FHH1099 - Agenda

Regulatory Strategy for a New Active Substance: Non-clinical Development

TOPRA, 6th Floor, 3 Harbour Exchange, South Quay, London E14 9GE, UK

20 - 22 October 2021

Day 1 - Wednesday 20th October Registration 13:30- 14:00 14:05 Start of Module **Chairperson:** Lesley Reeve **Welcome and Introduction** 14:05 - 14:20 Laura Brown, Course Director Lesley Reeve, Module Leader 14:25 - 15:15 Non-clinical Studies in Drug Natalie Burden Development NC3Rs 15:20 - 16.10 **Selection of a Candidate Compound:** Liz Martin Studies to Identify Likely Candidates AstraZeneca 16:10 - 16:30 **TEA** 16:30 - 17:20 Overall Non-clinical Package and Lesley Reeve Strategic Planning Covance 17.20 -Case study (Group work) Lesley Reeve Covance

<u>Day 2 - Thursday 21st October</u>			
	Chairperson: Lesley Reeve		
09:30 - 10:30	Safety Pharmacology Studies	Will Redfern	
		Certara	
10:30 - 10:50	COFFEE		
10:55 - 11:55	Introduction to Pharmacokinetics and Application to Drug Development	Peter Kilford	
		Certara	
12:00 - 13:00	General Toxicology and Carcinogenicity Testing	Andy Gibbs Covance	
13:00 - 13:50	LUNCH		
13:55 - 14:55	Genotoxicity Testing	Jon Howe GSK	
15:00 - 16:00	Reproductive Toxicology Testing – What and Why?	Jane Stewart Apconix	
16:05 -	Case Study (Group work)	Lesley Reeve	
	(includes TEA)	Covance	

Day 3 - Friday 22nd October

	Chairperson: Lesley Reeve	
09:30- 10:00	Environmental Risk Assessment	Ainsley Jones FERA
10:05 - 10:45	Toxicology Support for Paediatric Development	Paul Baldrick Covance
10:45 - 11:05	COFFEE	
11:05 - 11:55	Specific Nonclinical Considerations Associated with Biotechnology Products	Alison Wolfreys UCB
12:00 - 12:50	Specific Nonclinical Considerations Associated with Cell and Gene Therapy Products	Michaela Sharpe Moare Solutions Ltd.
12:50 - 13:45	LUNCH	
13:45 - 14:45	Agency Review Process / Data Presentation Problems	David Jones MHRA
14:45 - 15:45	Case study and Feedback (includes TEA)	AII
15:45 - 16:00	Close of Module	